With the data you can find out the actual test volume for specific markers or assays for infectious diseases, cancers, cardiac conditions, thyroid functions, etc. such as Troponin T, BNP, HIV , PSA, AFP etc. in key markets in Asia.
Singapore (PRWEB) July 5, 2008
Clearstate, a premier research consulting firm offering intelligence and specialized marketing information services in medical diagnostics, announced today the introduction of the Gateway's Assay Insights, the first in-depth in-vitro diagnostics (IVD) assay database to report volume and value demand of Clinical Diagnostics assays by type of test and brand in major Asian markets. The Gateway is a medical device market intelligence data service division of Clearstate.
"The Assay Insights is an extended tool of our current Gateway IVD installation database. We know from our clients that equipment installation data alone is not sufficient to allow them to effectively plan their business strategies. As competition heats up, knowing the demand for assay types, understand which assay types competing brands are pushing, allows our client to make informed investment decisions that could result in direct ROI," said Mr. Wilson Tan, Head of the Gateway.
Mr. Tan said that the Assay Insights is designed to provide actual and accurate laboratory consumption of assays in Immunoassays and Molecular Diagnostics. "With the data you can find out the actual test volume for specific markers or assays for infectious diseases, cancers, cardiac conditions, thyroid functions, etc. such as Troponin T, BNP, HIV , PSA, AFP etc. in key markets in Asia."
The Assay Insights categorizes Immunoassays into 8 segments, namely infectious diseases, tumour markers, cardiac markers, fertility/reproduction, anemia/adrenal, thyroid functions , bone markers, and toxicology, and analyzes these data based on actual demand by supplier brands, laboratory test volume size and geographical distribution.
For the initial launch, the Assay Insights will be available for China and India by the end of August 2008. This first dataset will have complete annual results for 2007, with subsequent update provided on a semi-annual basis.
The assay demand data is collected from major laboratories running Immunochemistry and Molecular Diagnostics tests. A total of 400 laboratories are surveyed in China and 300 laboratories are surveyed in India. These laboratories were pre-screened during the Gateway installation survey for their relevance, which means they must run Immunochemistry and/or Molecular Diagnostics tests. The sample size represents over 60% of the total universe of relevant laboratories and are deliberately focused on the higher test volume facilities.